83% of pharma's trials published

Share this article:

More than eight out of 10 pharma-sponsored clinical trials made it into a peer-reviewed journal, a 23% increase over the 2008 rate, researchers showed.

Executives interviewed think the hike is likely driven by more stringent demands for investigators to publish, said research firm Cutting Edge Information.

Drug companies are holding investigators more accountable for publishing to journals, the firm said. Many write publication clauses in contracts, making final milestone payments conditional on publication of trial results.

One drug company no longer accepts proposals from investigators unwilling to agree to write trial data up for publication, Cutting Edge said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?